Oncology Based In-vivo CRO Market

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible. Oncology Based In-vivo CRO Market focus on Oncology Based In-vivo CRO.

Oncology Based In-vivo CRO Market contains market size and forecasts of Oncology Based In-vivo CRO in Global, including the following market information:

Global Oncology Based In-vivo CRO Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Oncology Based In-vivo CRO market was valued at 1057.5 million in 2021 and is projected to reach US$ 1541.6 million by 2028, at a CAGR of 5.5% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Blood Cancer Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Oncology Based In-vivo CRO include Crown Bioscience, Charles River Laboratory, ICON Plc., Eurofins Scientific, Taconic Biosciences, Covance, EVOTEC, The Jackson Laboratory and Wuxi AppTec., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Oncology Based In-vivo CRO companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Oncology Based In-vivo CRO Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Oncology Based In-vivo CRO Market Segment Percentages, by Type, 2021 (%)

Blood Cancer

Solid Tumors

Other

Global Oncology Based In-vivo CRO Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Oncology Based In-vivo CRO Market Segment Percentages, by Application, 2021 (%)

Pharmaceutical & Biopharmaceutical Industries

Medical Device Companies

Others

Global Oncology Based In-vivo CRO Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Oncology Based In-vivo CRO Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Oncology Based In-vivo CRO revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Oncology Based In-vivo CRO revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Crown Bioscience

Charles River Laboratory

ICON Plc.

Eurofins Scientific

Taconic Biosciences

Covance

EVOTEC

The Jackson Laboratory

Wuxi AppTec.

MI Bioresearch, Inc.

Champion Oncology, Inc.

Xentech